Early antiarrhythmic drugs boost survival in shock-refractory cardiac arrest
AT ACC 16
An important footnote is that ALPS utilized a new, Food and Drug Administration–approved formulation of amiodarone, known as Nexterone, designed to reduce hypotensive effects. Had investigators employed the more familiar version of the drug, the safety results wouldn’t have been as good.
Out-of-hospital cardiac arrest accounts for roughly 350,000 deaths per year in the United States
Simultaneously with Dr. Kudenchuk’s presentation of the ALPS findings at ACC 16 in Chicago, the results were published online (N Engl J Med. 2016 Apr 4; doi: 10.1056/NEJMoa1514204).
He reported having no financial conflicts regarding the ALPS study, which was funded by the National Heart, Lung, and Blood Institute, the Canadian Institutes of Health Research, the American Heart Association, the U.S. Army, and Defense Research and Development Canada.
